President of the European Oncology Nursing Society, Johan de Munter, discusses the key take-home messages from his Nurses Group Keynote Lecture at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, 23-26 April 2023. Questions: Please summarise the key points from your Nurses Group Keynote Lecture presented at the EBMT conference 2023 (00:18) […]

The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. touchHAEMATOLOGY caught up with Dr Marina Kremyanskaya (Icahn School of Medicine at Mount Sinai, NY, USA) to discuss the main findings of the REVIVE study and the […]

The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. The unmet needs in the treatment of polycythaemia vera and the aims, rationale and methodology of the REVIVE study are discussed in this touchHAEMATOLOGY interview with Dr […]

In this interview, touchHAEMATOLOGY are joined by Professor Per Ljungman (Karolinska University Hospital, Stockholm, Sweden) to discuss the updated results of the EBMT COVID-19 Task Force study exploring study exploring the outcomes and mortality in cytomegalovirus seropositive allogeneic stem cell transplantation patients with COVID-19. Questions 1. Please describe the rationale and main aims of your […]

Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), summarizes the main take-home messages from her educational session on the latest improvements in autologous stem cell transplantation for patients with Hodgkin lymphoma. These include the introduction of new drugs in the salvage setting such as checkpoint inhibitors, improvements to long-term […]

Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), shares updates from the joint EBMT-EHA session on GoCART. This is a multi-stakeholder coalition of patient representatives, health care professionals, pharmaceutical companies, regulators, Health Technology Assessment bodies and reimbursement agencies, and medical organisations, collaborating to maximise the potential of cellular therapies […]

Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), shares updates from the HARMONY Alliance, a partnership of more than 100 European organizations such as hospitals, research institutes, patient organizations, pharmaceutical companies, regulatory agencies, IT companies and medical associations such as EBMT and EHA. The joint mission is to accelerate […]

Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), shares her highlights from the 49th Annual Meeting held in Paris, the first in-person event in three years. These include advances in treating major complications of transplantation in both adults and paediatric patients and further knowledge in managing new cellular therapies such as CAR-T. Disclosures: Anna […]

Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (allo-HCT) is the current recommended treatment. Professor Robin Foà (Sapienza University of Rome, Italy) joins us after the EBMT23 meeting to discuss his perspective on the ongoing debate of whether we should transplant all patients with Philadelphia Ph+ […]